1 source
The source names a leading sovereign wealth fund but does not identify it; it is not listed as an investor. The Austin dateline does not establish headquarters.
Published by hand (ollin.bio): "Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026": Checked by hand: Ollin's own release states the $330M Series B.
1 source
No financing stage, valuation, financing total, headquarters, or additional participating investors are stated.; not on the page it cites, so not applied: date
Published by hand (biopharmadive.com): "Called Ollin Biosciences, the startup emerged from stealth on Wednesday with $100 million in financing and medicines it aims to prove are superior to Roche’s vision loss drug Vabysmo and Amgen’s thyroid eye disease treatment Tepezza.": Checked by hand: BioPharma Dive states the $100M launch financing.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $330M | 2026-06-24 | TCGX, Arch Venture Partners | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The source names a leading sovereign wealth fund but does not identify it; it is not listed as an investor. The Austin dateline does not establish headquarters. Published by hand (ollin.bio): "Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026": Checked by hand: Ollin's own release states the $330M Series B. | ||||
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-09-17 | Arch Venture Partners, Mubadala Capital, Monograph | No recent discussion |
1 source [ VERIFIED ] read against 1 source No financing stage, valuation, financing total, headquarters, or additional participating investors are stated.; not on the page it cites, so not applied: date Published by hand (biopharmadive.com): "Called Ollin Biosciences, the startup emerged from stealth on Wednesday with $100 million in financing and medicines it aims to prove are superior to Roche’s vision loss drug Vabysmo and Amgen’s thyroid eye disease treatment Tepezza.": Checked by hand: BioPharma Dive states the $100M launch financing. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: biopharmadive.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage | ||||